BioCardia Regained Nasdaq Compliance After Bid Price Dip
Public companies must maintain minimum share prices to avoid delisting risks and capital market volatility.
Updated on Sept. 22, 2026 in Public Companies
Live Poll
Do you trust the long-term prospects of small biotech companies that struggle with stock listing requirements?
BioCardia has regained compliance with the Nasdaq minimum bid price requirement after sustaining a closing price of at least $1 for 10 consecutive business days. The company previously faced delisting warnings after its stock traded below the $1 threshold for 30 consecutive business days.
Why it matters
Maintaining Nasdaq compliance is essential for small-cap companies to avoid forced delisting, which can trigger liquidity constraints and restrict access to institutional capital. Even with this regulatory hurdle cleared, the company faces ongoing pressure as it cautions that future compliance with bid requirements remains uncertain.
BioCardia, which holds a market capitalization of approximately $16.35 million, saw its shares decline 2.7% over the past 12 months. The stock's 52-week range spans from a $0.75 low to a $1.80 high.
The players
BioCardia
A developer of cardiovascular regenerative medicine therapies with a market capitalization of approximately $16.35 million.
Nasdaq
A global stock exchange operator that enforces minimum bid price requirements to maintain listing standards for publicly traded companies.
The details
To avoid delisting, BioCardia was required to demonstrate that its stock could maintain a closing bid price of at least $1 for a sustained 10-business-day window. Despite regaining compliance, the company experienced a 10.19% decline in after-hours trading following the announcement. This movement highlights the volatility often associated with small-cap firms struggling to remain above exchange-mandated pricing minimums.
Timeline
BioCardia received an initial non-compliance notice in August 2026.
The stock traded during the regular session on September 21, 2026.
Shares fell 10.19% in after-hours trading on September 21, 2026.
Market Landscape
The Nasdaq minimum bid price requirement serves as a key governance threshold for public companies to demonstrate market viability. Falling below this level often signals broader operational challenges and necessitates strict compliance strategies to avoid delisting.
Small-cap operators should monitor their stock performance against exchange minimums to avoid the administrative and reputational costs of a delisting notice. Compliance is not permanent, and management teams must prepare for ongoing volatility after a period of non-compliance.
The takeaway
Maintaining exchange compliance requires consistent market valuation that can fluctuate rapidly for smaller firms. Operators should prioritize tracking their 52-week price volatility to anticipate when a delisting warning might occur and prepare necessary capital strategies in advance.
Further reading
For broader trends affecting market listing standards, see the Public Companies section.
Live Poll
Do you trust the long-term prospects of small biotech companies that struggle with stock listing requirements?
